Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 172   

Articles published

BMY 55.77 +0.42 (0.76%)
price chart
Carl Icahn's Next Target: Bristol-Myers Squibb
Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co. Bristol-Myers Squibb has been the focus of several activist investors in recent months and on Tuesday the company shook up its board to satisfy other activist ...
Analyst Activity – Argus Reiterates Buy on Bristol-Myers Squibb Company ...  Market Exclusive
Bristol-Myers Squibb Co (NYSE:BMY) To Sell Senior Notes As Formidable Activist ...
Bristol-Myers Squibb Co (NYSE:BMY) will sell senior notes that are unsecured worth $1.5 billion. Half of that amount is due in two years at a rate of 1.6% while the other half is due in a decade at a rate of 3.25%.
Bristol-Myers Looms as Pharma's Next Megadeal as Activists Join  Bloomberg
Forward Earnings Estimate of Bristol-Myers Squibb Company(BMY)  Highland Mirror
Bristol-Myers Squibb Appoints Three New Independent Directors
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has appointed Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuels to its Board of Directors, effective immediately.
Bristol-Myers Squibb Co (NYSE:BMY), Merck & Co., Inc. (NYSE:MRK), And Other ...
Reports indicate that the market for immuno-oncology drugs could grow to $25 billion in the next ten years. Pharmaceutical firms such as Bristol-Myers Squibb Co (NYSE:BMY) and Merck & Co., Inc. (NYSE:MRK) are already angling for a share of the market ...
Bristol-Myers Squibb Co. Bottom Line Advances 64% In Q4
(RTTNews.com) - Bristol-Myers Squibb Co. ( BMY ) announced earnings for its fourth quarter that gained ground compared to the same period last year.
Bristol-Myers Squibb cuts outlook  MarketWatch
Earnings Preview: What To Expect From Bristol-Myers Squibb On Thursday  Forbes
National Agreement Reached between Pan-Canadian Pharmaceutical Alliance and ...
MONTREAL, Feb. 10, 2017 /CNW/ - Bristol-Myers Squibb Canada Co. today announced that the company has reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for the immuno-oncology treatment OPDIVO�, bringing patients ...
Company Update (NYSE:BMY): Bristol-Myers Squibb Co Wins FDA Approval For ...
Bristol-Myers Squibb Co (NYSE:BMY) announced the U.S. Food and Drug Administration (FDA) has approved Opdivo injection, for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease ...
Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC  Yahoo Finance
UPDATE: Bristol-Myers Squibb (BMY) Gains FDA Accelerated Approval for Opdivo ...  StreetInsider.com
Wall Street's M&A Chatter From February 21
B. Riley Financial, Inc. (NASDAQ: RILY) announced an agreement to acquire FBR & Co. (NASDAQ: FBRC) in a transaction valued at $160.1 million.
Jana Partners Buys HD Supply Holdings, Bristol-Myers Squibb Company ...
Jana Partners initiated holdings in Bristol-Myers Squibb Company. The purchase prices were between $49.23 and $59.61, with an estimated average price of $54.67.
These 2 Factors Sent Bristol-Myers Squibb Co. Tumbling by 16% in January
Shares of global drug giant Bristol-Myers Squibb (NYSE: BMY) were hammered in January, falling 16% according to data from S&P Global Market Intelligence.
3 Big Stock Charts for Monday: Bristol-Myers Squibb Co (BMY), Visa Inc (V ...  Investorplace.com
Stock Price of Bristol-Myers Squibb Company (BMY) Increases 6.37%  Highland Mirror